Overview
Balance Sheet
Cash Flow
Growth Analysis
2023
2022
2021
2020
2019
Profitability Metrics
Gross Margin
38.09%
Operating Margin
9.65%
Net Margin
-54.00%
Efficiency Metrics
Revenue per Expense Ratio
1.11
R&D as % of Revenue
0.00%
Earnings Quality
EBITDA Margin
37.70%
Income Tax Rate
-5,530,000,000.0%
EPS
-2.4600000000
Balance Sheet Analysis
Current Ratio
1.11
Cash Ratio
0.51
Working Capital
$70.40M
Debt to Equity
3.02
Debt to Assets
68.81%
Equity Ratio
22.76%
Cash Flow Analysis
Operating Cash Flow Ratio
25.12%
Free Cash Flow Ratio
-13.49%
CapEx to Revenue
38.61%
Dividends Paid
$171.50M
Stock Buybacks
$20.90M
Total Shareholder Returns
$192.40M
Cash Position Change
-28.59%
Key Takeaways (2023 FY)
Increased dividend payments by 5.29%
Detailed Growth Metrics
Core Performance
Revenue
4.19%
Net Income
-424.23%
EPS
-461.76%
Operating Income
-76.15%
Operational Efficiency
R&D Expenses
-100.00%
SG&A Expenses
-7.62%
Operating Cash Flow
48.63%
Free Cash Flow
-31.48%
Balance Sheet Health
Assets
-6.77%
Debt
-5.17%
Book Value per Share
-11.85%
Inventory
100.00%
Shareholder Returns
Dividends per Share
5.29%
Shares Outstanding
1.48%
Long Term Trends
3Y Revenue/Share
25.50%
5Y Revenue/Share
-25.19%
3Y Dividend/Share
23.48%
5Y Dividend/Share
37.38%